CytomX Therapeutics, Inc. CTMX
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is an oncology drug developer. Its lead program, Varsetatug Masetecan (Varseta-M), is in Phase 1 for metastatic colorectal cancer (mCRC), later expanding to other EpCAM-expressing tumors. Its next catalyst on record is Varseta-M + bevacizumab + 5-FU + leucovorin: Phase 1/2 combination study initiation (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Varseta-M + bevacizumab + 5-FU + leucovorin — Phase 1/2 combination study initiation (Q4 2026). 8 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Varsetatug Masetecan (Varseta-M) | metastatic colorectal cancer (mCRC) | antibody | Phase 1 |
| Varseta-M + bevacizumab | metastatic colorectal cancer (mCRC) | antibody | Phase 1 |
| Varseta-M + bevacizumab + 5-FU + leucovorin | 2nd line metastatic colorectal cancer | antibody | Phase 1 |
| Varseta-M (expansion cohorts) | gastric/GEJ, PDAC, BTC | antibody | Phase 1 |
| CX-801 | advanced melanoma | protein/peptide | Phase 1 |
| CX-904 (EGFRxCD3) | solid tumors | biologic-other | Pre-clinical |
| Regeneron PROBODY bispecific collaboration programs | oncology | biologic-other | Pre-clinical |
Recent results and decisions
- positive Varseta-M granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer in August 2026.
Announced FDA Fast Track Designation for Varseta-M for relapsed/refractory metastatic colorectal cancer in August.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.